anything over 25mil, page-22

Also, it sounds like a lot of 'low ball' guesswork going on with the expected share price. Can you really see ANP only holding a market cap of 3-5c (30-50 million) when ATL1103 does to humans what it done on primates... Somaverts' sales alone are worth 200 million per annum, and although we would be undercutting them by 50% ($100 million to ANP) a market cap that low would just see us eaten up in a heartbeat by anyone with half a brain - probably even ISIS themselves. And that isn't taking into account the 35-40% of acromegalics who are not controlled on somatostatins - market opportunity of up to $500 million per annum in acromegaly indication.

I realise we are only P1 but the Doctors involved seem aware of what side effects are expected with what is being done and are bullish in some of their comments about how minimal they are and will be in comparison to Somavert... and again the benefits would outweigh the downside same as Somavert???

Mark Diamonds comments in announcement 9th of June

"ATL1103 is an exciting clinical development opportunity that has successfully passed through the research and pre-clinical stages of development where ATL1103 significantly reduced expression of the target (GHr) and suppressed serum IGF-I levels in both mice and primates. ATL1103 has also successfully completed toxicology (safety) studies. We are very excited about the clinical potential of this drug"

Just my opinion but we are looking good for incredible gains over the next 6 months...

Again JMO, DYOR and good luck!